Payment overview · 2025
General Payments
$715.67
28 reported records · 14 companies
Healthcare provider profile · identity verified
Cameron Vaughn Williams, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PLYMOUTH MEETING, PA · NPI 1902395957
Verified facts
What the public records show
CMS Open Payments records show Cameron Vaughn Williams, DO received $715.67 in general payments during 2025 across 28 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lokelma, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lokelma by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $205.90 | 28.8% | 7 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $117.05 | 16.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $75.07 | 10.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.45 | 10.4% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $51.61 | 7.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.56 | 5.8% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.71 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.39 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.08 | 2.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.85 | 2.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.63 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.44 | 2.6% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $17.40 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.53 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $643.17 | 27 |
| Education | $72.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $133.40 | 6 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $117.05 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $75.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $74.45 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 199 |
| Eliquis | Apixaban | 320 | 85 |
| Gabapentin | Gabapentin | 316 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 110 |
| Tramadol Hcl | Tramadol Hcl | 280 | 79 |
| Mirtazapine | Mirtazapine | 262 | 57 |
| Furosemide | Furosemide | 258 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 60 |
| Oxycodone Hcl | Oxycodone Hcl | 222 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 73 |
| Metformin Hcl | Metformin Hcl | 200 | 59 |
| Lorazepam | Lorazepam | 198 | 89 |
| Divalproex Sodium | Divalproex Sodium | 191 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 59 |
| Lisinopril | Lisinopril | 163 | 63 |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | 30 |
| Clonazepam | Clonazepam | 150 | 46 |
| Losartan Potassium | Losartan Potassium | 145 | 56 |
| Sertraline Hcl | Sertraline Hcl | 136 | 42 |
| Carvedilol | Carvedilol | 134 | 46 |
| Omeprazole | Omeprazole | 134 | 53 |
| Trazodone Hcl | Trazodone Hcl | 123 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 39 |
| Pregabalin | Pregabalin | 101 | 28 |
| Morphine Sulfate | Morphine Sulfate | 92 | 30 |
| Lacosamide | Lacosamide | 89 | 15 |
| Donepezil Hcl | Donepezil Hcl | 88 | 23 |
| Buspirone Hcl | Buspirone Hcl | 82 | 20 |
| Levetiracetam | Levetiracetam | 81 | 25 |
| Rexulti | Brexpiprazole | 75 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Latanoprost | Latanoprost | 68 | 22 |
| Tradjenta | Linagliptin | 68 | suppressed |
| Nifedipine Er | Nifedipine | 67 | 21 |
| Risperidone | Risperidone | 66 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 17 |
| Simvastatin | Simvastatin | 59 | 24 |
| Prednisone | Prednisone | 54 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 18 |
| Potassium Chloride | Potassium Chloride | 51 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 16 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Nystatin | Nystatin | 47 | 23 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Gemtesa | Vibegron | 44 | suppressed |
| Famotidine | Famotidine | 42 | 16 |
| Lactulose | Lactulose | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 13 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | 13 |
| Midodrine Hcl | Midodrine Hcl | 39 | 14 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 27 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 32 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 17 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 13 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Clobazam | Clobazam | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | 16 |
| Olanzapine | Olanzapine | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 11 |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | 13 |
| Enulose | Lactulose | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clozapine | Clozapine | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $715.67 · 28 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, CREXONT, INGREZZA, INJECTAFER, INVEGA SUSTENNA, Kerendia, LOKELMA, MOUNJARO, NUPLAZID, Ohtuvayre, REXULTI, VYVGART HYTRULO, WAINUA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lokelma play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error